|
"blanc j"的相關文件
顯示項目 1-6 / 6 (共1頁)
1
每頁顯示[10|25|50]項目
| 國家衛生研究院 |
2018-10 |
Impact of dose reduction or dose delay on the efficacy of liposomal irinotecan (nal-IRI)+5-fluorouracil/leucovorin (5-FU/LV): Survival analysis from NAPOLI-1
|
Chen, LT;Macarulla, TM;Blanc, J;Mirakhur, B;de Jong, FA;Belanger, B;Bekaii-Saab, T;Siveke, J |
| 國家衛生研究院 |
2018-06 |
Prognostic value of baseline biliary stents on outcomes in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) in the NAPOLI-1 trial
|
Lakatos, G;Lee, K;Siveke, J;Blanc, J;Mercade, TM;Dean, A;Bodoky, G;Mirakhur, B;Chen, J;Wang-Gillam, A;Chen, L;de Jong, F |
| 國家衛生研究院 |
2018-06 |
The effect of best response to prior anticancer therapy on efficacy outcomes in the napoli-1 trial of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy
|
Mercade, TM;Wang-Gillam, A;Chen, L;Blanc, J;Lee, K;Bodoky, G;Dean, A;Chen, J;Mirakhur, B;Siveke, J;de Jong, F |
| 國家衛生研究院 |
2018-06 |
Decreased appetite (DA) at baseline impacts prognosis in the NAPOLI-1 phase 3 study in metastatic pancreatic ductal adenocarcinoma (mPDAC)
|
Lee, K;Bodoky, G;Blanc, J;Siveke, J;Mercade, TM;Wang-Gillam, A;Chen, L;Mirakhur, B;Chen, J;de Jong, F |
| 國家衛生研究院 |
2018-06 |
Prognostic effect of primary tumor location in the NAPOLI-1 phase 3 study in metastatic pancreatic ductal adenocarcinoma (mPDAC)
|
Mercade, TM;Wang-Gillam, A;Chen, L;Blanc, J;Lee, K;Bodoky, G;Dean, A;Siveke, J;Mirakhur, B;Chen, J;de Jong, F |
| 國家衛生研究院 |
2016-09 |
Effects of nanoliposomal irinotecan (nal-IRI; MM-398) +/- 5-fluorouracil and leucavorin (5-FU/LV) on quality of life (QoL) in patients (pts) with metastatic pancreatic adenocarcinoma (mPAC) previously treated with gemcitabine-based therapy: Results from t
|
Melisi, D;Melisi, D;Siveke, JT;Blanc, J;Von Hoff, DD;Wang-Gillam, A;Chen, L;Becker, C;Mamlouk, K;De Jong, F;Hubner, R |
顯示項目 1-6 / 6 (共1頁)
1
每頁顯示[10|25|50]項目
|
